Posted by Michael Wonder on 06 Oct 2022
HHS implements inflationary rebates for list prices of Medicare Part D (outpatient) drugs
5 October 2022 - On 1 October, the Department of Health and Human Services began implementing one of three main prescription drug pricing provisions contained in the Inflation Reduction Act.
The Department of Health and Human Services now requires that drug manufacturers pay the Centers for Medicare and Medicaid Services rebates for raising list prices of outpatient drugs for Medicare in excess of inflation.
